SGMO - Sangamo Therapeutics Inc
IEX Last Trade
0.8473
0.022 2.620%
Share volume: 1,854,331
Last Updated: Fri 30 Aug 2024 09:59:26 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$0.83
0.02
2.69%
Fundamental analysis
8%
Profitability
0%
Dept financing
12%
Liquidity
50%
Performance
5%
Performance
5 Days
-1.12%
1 Month
21.14%
3 Months
55.54%
6 Months
-20.75%
1 Year
-10.55%
2 Year
-84.09%
Key data
Stock price
$0.85
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.29 - $1.48
52 WEEK CHANGE
-$0.14
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
Company detail
CEO: Alexander Macrae
Region: US
Website: https://www.sangamo.com/
Employees: 520
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: https://www.sangamo.com/
Employees: 520
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
for sangamo therapeutics, science is a means to develop new medicines with the potential to transform the lives of patients living with serious genetic diseases. our scientists are leaders in the discovery, research and development of technologies enabling gene-based therapeutic development. currently we are conducting clinical trials, including the first ever in vivo human genome editing studies. to learn more about sangamo, visit the our website at www.sangamo.com.
Recent news